Open AccessCyclophosphamide‐induced bladder toxicity in wegener's granulomatosis
Author(s) -
Stillwell Thomas J.,
Benson Ralph C.,
Deremee Richard A.,
Mcdonald Thomas J.,
Weiland Louis H.
Publication year - 1988
Publication title -
arthritis & rheumatism
Language(s) - English
Resource type - Journals
eISSN - 1529-0131
pISSN - 0004-3591
DOI - 10.1002/art.1780310402
Subject(s) - cyclophosphamide , toxicity , medicine , wegener granulomatosis , dermatology , pathology , systemic disease , immunopathology , chemotherapy
In a series of 111 patients with Wegener's granulomatosis who were given cyclophosphamide therapy, hemorrhagic cystitis, diagnosed on the basis of gross hematuria or at cystoscopy (or both), developed in 17 (15%). Most of these patients recovered uneventfully, with or without the discontinuation of cyclophosphamide, but 4 patients suffered a significant loss of blood, and bladder carcinoma developed in 3. New microhematuria also occurred in 52 patients (47%). The dose and duration of cyclophosphamide were greater in the group that had urotoxicity. Long‐term followup of patients with hemorrhagic cystitis is mandatory for the detection of late recurrences or the development of bladder malignancy. New therapies are being directed at protecting the bladder from urotoxicity during cyclophosphamide treatment.